Menu
  • About RedHill
  • Products
  • Partnering
  • Investors
  • News
  • Contact
  • CAREERS
  • Press Releases

    Date Summary View
    Toggle Summary RedHill Biopharma Prices Public Offering of its American Depositary Shares
    TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 08, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
    View HTML
    Toggle Summary RedHill Biopharma Announces Proposed Public Offering of its American Depositary Shares
    TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
    View HTML
    Toggle Summary RedHill Biopharma to Host Third Quarter 2017 Financial Results Conference Call on November 13, 2017
    TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 06, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
    View HTML
    Toggle Summary RedHill Biopharma Announces EnteraGam® Poster Presentation at the ISPOR 20th Annual European Congress
    TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 06, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
    View HTML
    Toggle Summary RedHill Biopharma and IntelGenx Submit New Drug Application to FDA for RIZAPORT® for Migraines
    RIZAPORT ® is a proprietary oral thin-film formulation of rizatriptan for the treatment of acute migraines A Prescription Drug User Fee Act (PDUFA) date is expected to be set by the FDA for the first half of 2018, if the submission is deemed complete and permits a full review RIZAPORT ® (5mg and ...
    View HTML
    Toggle Summary RedHill Biopharma to Present at the BIO-Europe 2017 Conference
    TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 26, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, ...
    View HTML
    Toggle Summary RedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering RHB-104
    The new patent, covering RHB-104 for relapsing-remitting multiple sclerosis (MS), is expected to be valid until 2032, once granted Enrollment in the Phase III study with RHB-104 for Crohn's disease to be completed in November 2017 and top-line results expected in Q3/2018 A pivotal Phase III study ...
    View HTML
    Toggle Summary RedHill Biopharma Receives FDA Orphan Drug Designation for MESUPRON for Pancreatic Cancer
    RedHill to benefit from various incentives to develop MESUPRON (upamostat) for the adjuvant treatment of pancreatic cancer, including a seven-year marketing exclusivity period for the indication, if approved   MESUPRON is a proprietary, first-in-class, orally-administered protease inhibitor, with ...
    View HTML
    Toggle Summary RedHill Biopharma Announces Poster Presentation at the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
    TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 19, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, ...
    View HTML
    Toggle Summary RedHill Biopharma to Present at the BioNetwork 2017 Partnering Summit
    TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 10, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, ...
    View HTML